Arrhythmias & electrophysiologyMeta-analysis
Sodium–glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis
- Systematic review and meta-analysis of randomised trials
- placebo-controlled trials
Authors' conclusion
For patients with cardiometabolic diseases or risk factors, SGLT2 inhibitors did not decrease the risk of AF occurrence, regardless of follow-up duration, type or dose of the drug, or the patient population.
Study context
- Population
- Patients with DM, HF, CKD or cardiometabolic risk factors
- Participants
- 101,100 patients · 46 RCTs
- Comparison
- SGLT2 inhibitors vs placebo
- Outcome
- AF occurrence
Pooled result
As reported in the abstract
Relative risk
0.90
95% CI 0.80–1.01
SGLT2 inhibitors vs Placebo
RR 0.90 (95% CI 0.80–1.01)
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| AF occurrence, by SGLT2 inhibitor — Canagliflozin vs Placebo | 0.82 (0.60–1.12) | |
| AF occurrence, by SGLT2 inhibitor — Dapagliflozin vs Placebo | 0.87 (0.73–1.03) | |
| AF occurrence, by SGLT2 inhibitor — Empagliflozin vs Placebo | 0.97 (0.78–1.22) | |
| AF occurrence, by SGLT2 inhibitor — Sotagliflozin vs Placebo | 0.99 (0.66–1.50) | |
| AF occurrence, by SGLT2 inhibitor — Ertugliflozin vs Placebo | 0.87 (0.58–1.29) | |
| 0.512Relative risk (log scale) |
Atrial fibrillation (AF) occurrence, by dose and in DM, HF and CKD subgroups
- Similar results across doses; no association in patients with DM, HF or CKD
Original publication
Sodium–glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis. Eur J Prev Cardiol. Published 15 November 2023. doi:10.1093/eurjpc/zwad356
Summarised from the published abstract; every number is checked against it